NCT00126893View on ClinicalTrials.gov

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2005

Study Completion Date

September 30, 2006

Conditions
Myeloid Leukemia
Interventions
DRUG

CC-401

Trial Locations (1)

46202-5149

Indiana University Medical Center, Indianapolis

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY